Julia Thornton Snider

9PUBLICATIONS
60CO-AUTHORS
Epidemiological modellingPanel data analysisHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 07, 2025
Evaluating the Role and Policy Implications of Using External Evidence in Survival Extrapolations: A Case Study of Axicabtagene Ciloleucel Therapy for Second-Line DLBCL.

Sam Harper, Daniela Afonso, Karina Watts

|Jun 06, 2023
Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.

Diane Ito, Chaoling Feng, Christine Fu

|Mar 31, 2023
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.

Jason R Westin, Frederick L Locke, Michael Dickinson

|Sep 01, 2022
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.

Olalekan O Oluwole, Jenny M H Chen, Keith Chan

|Jul 15, 2022
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.

Mahmoud Elsawy, Julio C Chavez, Irit Avivi

|Jun 11, 2022
Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.

Alice Kate Cummings Joyner, Julia Thornton Snider, Sally West Wade

Pageof 2

Frequent Collaborators

4 joint publications

Olalekan O Oluwole

4 joint publications

Frederick L Locke

2 joint publications

John Radford

2 joint publications

Ibrahim Diakite